Neonatal screening for sickle haemoglobinopathies in Birmingham

Area of Science:

• Medical Genetics
• Neonatal Screening
• Hematology

Background:

• Sickle hemoglobinopathies represent a significant public health concern.
• Early detection of these conditions is crucial for timely intervention and improved outcomes.
• Neonatal screening programs offer a potential avenue for early identification.

Purpose of the Study:

• To assess the feasibility, cost, and benefits of early detection of sickle hemoglobinopathies in newborns.
• To evaluate the prevalence of various hemoglobinopathies in a diverse neonatal population.

Main Methods:

• Cellulose acetate electrophoresis was performed on red cell hemolysates from capillary specimens.
• Specimens were collected as part of routine phenylketonuria screening.
• Analysis focused on identifying carriers and affected individuals for hemoglobin S, C, E, D, and other variants.

Main Results:

• Eight infants were diagnosed with significant hemoglobinopathies: four with sickle cell disease (HbS homozygotes), three with HbS/HbC heterozygotes, and one with HbE/beta-thalassemia.
• Prevalence of HbS or HbD heterozygotes was 1.19%, HbC or HbE heterozygotes was 0.46%.
• The cost of screening was 12.5 pence per baby, with an estimated cost of 705 pounds per serious abnormality detected.

Conclusions:

• Neonatal screening for hemoglobinopathies using electrophoresis is feasible and identifies significant genetic blood disorders.
• The screening program proved cost-effective, particularly for detecting serious conditions like sickle cell disease.
• Early detection through neonatal screening facilitates timely management and can improve long-term health outcomes for affected infants.